SCMP SEC 보고서 - Sucampo Pharmaceuticals, Inc.- 연례 보고, 기업 사업 설명서, 유가증권계출서

기본 통계

CIK

1365216

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sucampo Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.

February 23, 2018	15-12B	SCMP / Sucampo Pharmaceuticals, Inc. 15-12B 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33609 SUCAMPO PHARMACEUTICALS, INC. (Exact name of registrant as
February 15, 2018	SC 13D/A	SCMP / Sucampo Pharmaceuticals, Inc. / Kuno Sachiko - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) David A. Rivard, Esquire McGuireWoods LLP 800 East Canal Street Richmond, VA 23219 (804) 775-1000 (Name,
February 15, 2018	SC 13D/A	SCMP / Sucampo Pharmaceuticals, Inc. / Ueno Ryuji - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) David A. Rivard, Esquire McGuireWoods LLP 800 East Canal Street Richmond, VA 23219 (804) 775-1000 (Name,
February 13, 2018	S-8 POS	SCMP / Sucampo Pharmaceuticals, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 13, 2018 Registration No.
February 13, 2018	S-8 POS	SCMP / Sucampo Pharmaceuticals, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 13, 2018 Registration No.
February 13, 2018	POS AM	SCMP / Sucampo Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on February 13, 2018 Registration No.
February 13, 2018	POS AM	SCMP / Sucampo Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on February 13, 2018 Registration No.
February 13, 2018	POS AM	SCMP / Sucampo Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on February 13, 2018 Registration No.
February 13, 2018	POS AM	SCMP / Sucampo Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on February 13, 2018 Registration No.
February 13, 2018	EX-3.2	Amended and Restated Bylaws of Sucampo Pharmaceuticals, Inc. EX-3.2 Exhibit 3.2 BY-LAWS of SUCAMPO PHARMACEUTICALS, INC. dated as of February 13, 2018 TABLE OF CONTENTS ARTICLE I OFFICES SECTION 1. REGISTERED OFFICE 1 SECTION 2. OTHER OFFICES 1 ARTICLE II MEETINGS OF STOCKHOLDERS SECTION 1. ANNUAL MEETINGS 1 SECTION 2. SPECIAL MEETINGS 1 SECTION 3. VOTING 1 SECTION 4. QUORUM 2 SECTION 5. NOTICE OF MEETINGS 2 SECTION 6. ACTION WITHOUT MEETING 2 ARTICLE III D
February 13, 2018	EX-4.2	Supplemental Indenture, dated as of February 13, 2018, between Sucampo Pharmaceuticals, Inc. and U.S. Bank National Association, as Trustee. EX-4.2 Exhibit 4.2 SUCAMPO PHARMACEUTICALS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of February 13, 2018 3.25% Convertible Senior Notes due 2021 FIRST SUPPLEMENTAL INDENTURE, dated as of February 13, 2018 (this ?Supplemental Indenture?), among Sucampo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), as issuer, and U.S. Bank National A
February 13, 2018	EX-3.1	Amended and Restated Certificate of Incorporation of Sucampo Pharmaceuticals, Inc. EX-3.1 Exhibit 3.1 CERTIFICATE OF INCORPORATION of SUCAMPO PHARMACEUTICALS, INC. ARTICLE I The name of the corporation is Sucampo Pharmaceuticals, Inc. (the ?Corporation?). ARTICLE II The address, including street, number, city, and county, of the registered office of the Corporation in the State of Delaware is c/o The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, City o
February 13, 2018	8-K	Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K 1 d527693d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 13, 2018 Sucampo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33609 30-0520478 (State or other juri
February 13, 2018	SC 14D9/A	SCMP / Sucampo Pharmaceuticals, Inc. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 7) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUCAMPO PHARMACEUTICALS, INC. (Name of Person Filing Statement) Class A Common Stock, par value $0.01 per share (T
February 13, 2018	EX-99.(B)(3)	Incremental Assumption Agreement No. 4, dated as of February 13, 2018, by and among Mallinckrodt plc, Mallinckrodt International Finance, S.A., Mallinckrodt CB LLC, the other subsidiaries of Mallinckrodt plc party thereto and Deutsche Bank AG New York Branch, as administrative agent (incorporated by reference to Exhibit (b)(3) of the Schedule TO/A filed with the SEC by Mallinckrodt plc and Sun Acquisition Co. on February 13, 2018). EX-99.(b)(3) Exhibit b(3) EXECUTION VERSION INCREMENTAL ASSUMPTION AGREEMENT NO. 4 INCREMENTAL ASSUMPTION AGREEMENT NO. 4, dated as of February 13, 2018 (this Amendment), to the Credit Agreement, dated March 19, 2014 (as amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the Credit Agreement; the Credit Agreement as amended hereby, the Amended Cr
February 13, 2018	SC TO-T/A	MNK / Maillinckrodt plc. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 8) SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUN ACQUISITION CO. (Offeror) MALLINCKRODT PUBLIC LIMITED COMPANY (Names of Filing Persons) CLASS A COMMON STOCK, PAR VA
February 13, 2018	EX-99.(A)(1)(I)	Press Release, dated February 13, 2018 (incorporated by reference to Exhibit (a)(1)(I) of the Schedule TO/A filed with the SEC by Mallinckrodt plc and Sun Acquisition Co. on February 13, 2018). EX-99.(a)(1)(I) Exhibit (a)(1)(I) MALLINCKRODT COMPLETES ACQUISITION OF SUCAMPO PHARMACEUTICALS, INC. STAINES-UPON-THAMES, United Kingdom, Feb. 13, 2018 /PR Newswire/?Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has closed the acquisition of Sucampo Pharmaceuticals, Inc, a global biopharmaceutical company, including its commercial and developm
February 13, 2018	SC 13G	SCMP / Sucampo Pharmaceuticals, Inc. / LSV ASSET MANAGEMENT Passive Investment SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SUCAMPO PHARMACEURICALS, INC.
February 13, 2018	SC 13G/A	SCMP / Sucampo Pharmaceuticals, Inc. / ING GROEP NV - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 864909106 (CUSIP Number) December 31, 2017 (Date of Event
February 12, 2018	SC TO-T/A	MNK / Maillinckrodt plc. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 7) SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUN ACQUISITION CO. (Offeror) MALLINCKRODT PUBLIC LIMITED COMPANY (Names of Filing Persons) CLASS A COMMON STOCK, PAR VA
February 12, 2018	SC 14D9/A	SCMP / Sucampo Pharmaceuticals, Inc. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 6) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUCAMPO PHARMACEUTICALS, INC. (Name of Person Filing Statement) Class A Common Stock, par value $0.01 per share (Title of Cl
February 9, 2018	SC TO-T/A	MNK / Maillinckrodt plc. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUN ACQUISITION CO. (Offeror) MALLINCKRODT PUBLIC LIMITED COMPANY (Names of Filing Persons) CLASS A COMMON STOCK, PAR VA
February 9, 2018	SC 14D9/A	SCMP / Sucampo Pharmaceuticals, Inc. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 5) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUCAMPO PHARMACEUTICALS, INC. (Name of Person Filing Statement) Class A Common Stock, par value $0.01 per share (T
February 8, 2018	SC TO-T/A	MNK / Maillinckrodt plc. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUN ACQUISITION CO. (Offeror) MALLINCKRODT PUBLIC LIMITED COMPANY (Names of Filing Persons) CLASS A COMMON STOCK, PAR VA
February 8, 2018	SC 13G	SCMP / Sucampo Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment us8649091068012418.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) SUCAMPO PHARMACEUTICALS INC - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 864909106 - (CUSIP Number) December 31, 2017 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
February 7, 2018	SC TO-T/A	MNK / Maillinckrodt plc. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUN ACQUISITION CO. (Offeror) MALLINCKRODT PUBLIC LIMITED COMPANY (Names of Filing Persons) CLASS A COMMON STOCK, PAR VA
February 5, 2018	SC 14D9/A	SCMP / Sucampo Pharmaceuticals, Inc. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUCAMPO PHARMACEUTICALS, INC. (Name of Person Filing Statement) Class A Common Stock, $0.01 par value per share (T
February 5, 2018	EX-99.(A)(8)	3 SUMMARY OF MATERIAL U.S. FEDERAL INCOME TAX IMPLICATIONS EX-(a)(8) Exhibit (a)(8) To: Holders of Sucampo Options and RSUs or Shares Purchased under the ESPP: Subject: Transaction Impact on Sucampo Options, RSUs and Shares On December 23, 2017, Sucampo Pharmaceuticals, Inc.
February 5, 2018	SC 14D9/A	SCMP / Sucampo Pharmaceuticals, Inc. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUCAMPO PHARMACEUTICALS, INC. (Name of Person Filing Statement) Class A Common Stock, $0.01 par value per share (T
January 30, 2018	SC TO-T/A	MNK / Maillinckrodt plc. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUN ACQUISITION CO. (Offeror) MALLINCKRODT PUBLIC LIMITED COMPANY (Names of Filing Persons) CLASS A COMMON STOCK, PAR VA
January 30, 2018	SC 14D9/A	SCMP / Sucampo Pharmaceuticals, Inc. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUCAMPO PHARMACEUTICALS, INC. (Name of Person Filing Statement) Class A Common Stock, $0.01 par value per share (Title of Cl
January 25, 2018	SC TO-T/A	MNK / Maillinckrodt plc. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUN ACQUISITION CO. (Offeror) MALLINCKRODT PUBLIC LIMITED COMPANY (Names of Filing Persons) CLASS A COMMON STOCK, PAR VA
January 25, 2018	SC 14D9/A	SCMP / Sucampo Pharmaceuticals, Inc. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUCAMPO PHARMACEUTICALS, INC. (Name of Person Filing Statement) Class A Common Stock, $0.01 par value per share (T
January 17, 2018	SC TO-T/A	MNK / Maillinckrodt plc. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUN ACQUISITION CO. (Offeror) MALLINCKRODT PUBLIC LIMITED COMPANY (Names of Filing Persons) CLASS A COMMON STOCK, PAR VA
January 17, 2018	EX-99.(A)(1)(H)	January 16, 2018 EX-99.(a)(1)(H) Exhibit (a)(1)(H) January 16, 2018 On January 16, Mallinckrodt announced the launch of an all-cash tender offer to acquire all outstanding shares of Class A common stock (the ?Sucampo Shares?) of Sucampo Pharmaceuticals, Inc. (?Sucampo?). As a Sucampo stockholder, you will be receiving an Offer to Purchase, a Letter of Transmittal, and other important documents. You should read the
January 16, 2018	EX-99.E.20	AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT EX-99.E.20 Exhibit (e)(20) AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the Agreement) is made by and between Sucampo Pharmaceuticals, Inc., its parent, subsidiary, predecessor and affiliated corporations (collectively Sucampo), and Peter Pfreundschuh (Executive), and amends, restates and supersedes the Employment Agreement dated
January 16, 2018	SC 14D9	SCMP / Sucampo Pharmaceuticals, Inc. SC 14D9 SC 14D9 1 d524880dsc14d9.htm SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUCAMPO PHARMACEUTICALS, INC. (Name of Person Filing Statement) Class A Common Stock, $
January 16, 2018	EX-99.E.18	AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT EX-99.E.18 Exhibit (e)(18) AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the Agreement) is made by and between Sucampo Pharmaceuticals, Inc., its parent, subsidiary, predecessor and affiliated corporations (collectively Sucampo), and Dr. Peter Kiener (Executive), and amends, restates and supersedes the Employment Agreement dated A
January 16, 2018	EX-99.E.15	EXECUTIVE EMPLOYMENT AGREEMENT EX-99.E.15 Exhibit (e)(15) EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the Agreement) is made by and between Sucampo Pharmaceuticals, Inc., its parent, subsidiary, predecessor and affiliated corporations (collectively Sucampo), and Alex Driggs (Executive). 1. Sucampo shall employ Executive as Senior Vice President, General Counsel, Corporate Secretary and Chief Compli
January 16, 2018	EX-99.E.14	AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT EX-99.E.14 Exhibit (e)(14) AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the Agreement) is made by and between Sucampo Pharmaceuticals, Inc., its parent, subsidiary, predecessor and affiliated corporations (collectively Sucampo), and Matthew Maxwell Donley (Executive, and amends, restates and supersedes the Employment Agreement da
January 16, 2018	EX-99.E.19	EXECUTIVE EMPLOYMENT AGREEMENT EX-99.E.19 Exhibit (e)(19) EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is made by and between Sucampo Pharmaceuticals, Inc., its parent, subsidiary, predecessor and affiliated corporations (collectively ?Sucampo?), and Jason Meyenburg (?Executive?), and amends, restates and supersedes in its entirety that certain employment letter agreement, dated December
January 16, 2018	EX-99.E.17	AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT EX-99.E.17 Exhibit (e)(17) AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the Agreement) is made by and between Sucampo Pharmaceuticals, Inc., its parent, subsidiary, predecessor and affiliated corporations (collectively Sucampo), and Peter Greenleaf (Executive), and amends, restates and supersedes the Employment Agreement dated Au
January 16, 2018	EX-99.E.16	AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT EX-99.E.16 Exhibit (e)(16) AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the Agreement) is made by and between Sucampo Pharmaceuticals, Inc., its parent, subsidiary, predecessor and affiliated corporations (collectively Sucampo), and Jones Woodrow Bryan, Jr. (Executive), and amends, restates and supersedes the Employment Agreement
January 16, 2018	EX-99.(B)(1)	DEUTSCHE BANK AG NEW YORK BRANCH DEUTSCHE BANK SECURITIES INC. 60 Wall Street New York, New York 10005 EX-99.(b)(1) Exhibit (b)(1) EXECUTION VERSION DEUTSCHE BANK AG NEW YORK BRANCH DEUTSCHE BANK SECURITIES INC. 60 Wall Street New York, New York 10005 December 23, 2017 Mallinckrodt International Finance S.A. 124, boulevard de la P?trusse L-2330 Luxembourg Attention: John Einwalter, Director Project Solero Commitment Letter Ladies and Gentlemen: Mallinckrodt International Finance S.A. (the ?Lux Borr
January 16, 2018	EX-99.(B)(2)	MALLINCKRODT INTERNATIONAL FINANCE S.A. 124, BOULEVARD DE LA PÉTRUSSE L-2330 LUXEMBOURG January 5, 2018 EX-99.(b)(2) Exhibit (b)(2) EXECUTION VERSION MALLINCKRODT INTERNATIONAL FINANCE S.A. 124, BOULEVARD DE LA P?TRUSSE L-2330 LUXEMBOURG January 5, 2018 DEUTSCHE BANK AG NEW YORK BRANCH DEUTSCHE BANK SECURITIES INC. 60 Wall Street New York, New York 10005 BARCLAYS BANK PLC 745 Seventh Avenue New York, New York 10019 CITIGROUP GLOBAL MARKETS INC. 390 Greenwich Street New York, New York 10013 CREDIT SU
January 16, 2018	EX-99.(A)(1)(D)	Offer to Purchase for Cash All Outstanding Shares of Class A Common Stock SUCAMPO PHARMACEUTICALS, INC. a Delaware corporation $18.00 NET PER SHARE Pursuant to the Offer to Purchase dated January 16, 2018 SUN ACQUISITION CO. a wholly owned indirect s EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Class A Common Stock of SUCAMPO PHARMACEUTICALS, INC. a Delaware corporation at $18.00 NET PER SHARE Pursuant to the Offer to Purchase dated January 16, 2018 by SUN ACQUISITION CO. a wholly owned indirect subsidiary of MALLINCKRODT PUBLIC LIMITED COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 8:00A.M., E
January 16, 2018	EX-99.1(A)(1)(C)	Offer to Purchase for Cash All Outstanding Shares of Class A Common Stock SUCAMPO PHARMACEUTICALS, INC. a Delaware corporation $18.00 NET PER SHARE Pursuant to the Offer to Purchase dated January 16, 2018 SUN ACQUISITION CO. a wholly owned indirect s EX-99.(a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase for Cash All Outstanding Shares of Class A Common Stock of SUCAMPO PHARMACEUTICALS, INC. a Delaware corporation at $18.00 NET PER SHARE Pursuant to the Offer to Purchase dated January 16, 2018 by SUN ACQUISITION CO. a wholly owned indirect subsidiary of MALLINCKRODT PUBLIC LIMITED COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 8:00 A.M.,
January 16, 2018	EX-99.(A)(1)(B)	LETTER OF TRANSMITTAL To Tender Shares of Class A Common Stock SUCAMPO PHARMACEUTICALS, INC. a Delaware corporation $18.00 NET PER SHARE Pursuant to the Offer to Purchase dated January 16, 2018 SUN ACQUISITION CO. a wholly owned indirect subsidiary o EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Class A Common Stock of SUCAMPO PHARMACEUTICALS, INC. a Delaware corporation at $18.00 NET PER SHARE Pursuant to the Offer to Purchase dated January 16, 2018 by SUN ACQUISITION CO. a wholly owned indirect subsidiary of MALLINCKRODT PUBLIC LIMITED COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 8:00 A.M., EASTERN TIM
January 16, 2018	EX-99.(A)(1)(A)	Offer to Purchase for Cash All Outstanding Shares of Class A Common Stock Sucampo Pharmaceuticals, Inc. $18.00 Net Per Share Sun Acquisition Co. a wholly owned indirect subsidiary of Mallinckrodt Public Limited Company THE OFFER AND WITHDRAWAL RIGHTS EX-99.(a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Class A Common Stock of Sucampo Pharmaceuticals, Inc. at $18.00 Net Per Share by Sun Acquisition Co. a wholly owned indirect subsidiary of Mallinckrodt Public Limited Company THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 8:00 A.M., EASTERN TIME, ON FEBRUARY 13, 2018, UNLESS THE OFFER IS EXTEND
January 16, 2018	EX-99.(A)(1)(G)	Notice of Offer to Purchase for Cash All Outstanding Shares of Class A Common Stock SUCAMPO PHARMACEUTICALS, INC. a Delaware corporation $18.00 NET PER SHARE Pursuant to the Offer to Purchase dated January 16, 2018 SUN ACQUISITION CO. a wholly owned EX-99.(a)(1)(G) Exhibit (a)(1)(G) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Sucampo Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is being made solely by the Offer to Purchase, dated January 16, 2018 and the related Letter of Transmittal and any amendment
January 16, 2018	SC TO-T	MNK / Maillinckrodt plc. SC TO-T SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUN ACQUISITION CO. (Offeror) MALLINCKRODT PUBLIC LIMITED COMPANY (Names of Filing Persons) CLASS A COMMON STOCK, PAR VALUE $0.01 PER SHARE
January 12, 2018	SC 13G/A	SCMP / Sucampo Pharmaceuticals, Inc. / Linden Capital L.P. - SC 13G/A Passive Investment SC 13G/A 1 d521225dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No.1)* Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 86490910
January 3, 2018	SC 13D/A	SCMP / Sucampo Pharmaceuticals, Inc. / Kuno Sachiko - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) David N. Oakey, Esquire McGuireWoods LLP 800 East Canal Street Richmond, VA 23219 (804) 775-1022 (Name,
January 3, 2018	SC 13D/A	SCMP / Sucampo Pharmaceuticals, Inc. / Ueno Ryuji - SC 13D/A Activist Investment SC 13D/A 1 d517450dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) David N. Oakey, Esquire McGuireWoods LLP 800 East Canal Street Richmond, V
January 2, 2018	8-K	SCMP / Sucampo Pharmaceuticals, Inc. FORM 8-K (Current Report) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 28, 2017 Date of Report (Date of earliest event reported) Sucampo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33609 30-0520478 (State or other jurisdiction of incorporat
December 27, 2017	SC14D9C	SCMP / Sucampo Pharmaceuticals, Inc. FORM SC 14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUCAMPO PHARMACEUTICALS, INC. (Name of Person Filing Statement) Class A Common Stock, $0.01 par value per share (Title of Class of Securities)
December 26, 2017	SC 14D9	SCMP / Sucampo Pharmaceuticals, Inc. SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 SUCAMPO PHARMACEUTICALS, INC. (Name of Subject Company) SUCAMPO PHARMACEUTICALS, INC. (Name of Person Filing Statement) Class A Common Stock, $0.01 par value per share (Title of Class of Securities)
December 26, 2017	8-K	SCMP / Sucampo Pharmaceuticals, Inc. FORM 8-K (Current Report) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 26, 2017 (December 22, 2017) Date of Report (Date of earliest event reported) Sucampo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33609 30-0520478 (State or other jurisd
December 26, 2017	EX-99.1	December 26, 2017 EX-99.1 Exhibit 99.1 December 26, 2017 Mallinckrodt to Acquire Sucampo Pharmaceuticals for Approximately $1.2 Billion ? Immediately accretive transaction includes development and commercial assets including AMITIZA? (lubiprostone), a leading product in branded constipation market ? ? Mallinckrodt expects accretion to 2018 adjusted diluted earnings per share of at least $0.30; and at least double t
December 26, 2017	EX-2.1	Agreement and Plan of Merger, dated as of December 23, 2017, by and among Sucampo Pharmaceuticals, Inc., Mallinckrodt plc and Sun Acquisition Co. EX-2.1 2 d521173dex21.htm EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: SUCAMPO PHARMACEUTICALS, INC., a Delaware corporation; MALLINCKRODT PLC, an Irish public limited company; and SUN ACQUISITION CO., a Delaware corporation Dated as of December 23, 2017 TABLE OF CONTENTS Page SECTION 1. THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 SECTION 2. MERGER TRANSACTION 5 2
December 26, 2017	EX-99.3	Investor Presentation, dated December 26, 2017. EX-99.3 Mallinckrodt Strategic Acquisition Sucampo Pharmaceuticals December 26, 2017 Exhibit 99.3 Forward-looking statements Statements in this document that are not strictly historical, including statements regarding the proposed acquisition of Sucampo Pharmaceuticals, the expected timetable for completing the transaction, future financial condition and operating results, benefits and synergies o
December 26, 2017	SC TO-C	MNK / Maillinckrodt plc. 8-K SC TO-C 1 d497443d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 26, 2017 (December 23, 2017) Mallinckrodt public limited company (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088
December 26, 2017	EX-2.1	Agreement and Plan of Merger, dated as of December 23, 2017, by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: SUCAMPO PHARMACEUTICALS, INC., a Delaware corporation; MALLINCKRODT PLC, an Irish public limited company; and SUN ACQUISITION CO., a Delaware corporation Dated as of December 23, 2017 TABLE OF CONTENTS Page SECTION 1. THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 SECTION 2. MERGER TRANSACTION 5 2.1 Merger of Purchaser int
December 26, 2017	EX-99.1	Tender and Support Agreement, dated as of December 23, 2017, by and among Mallinckrodt plc, Sun Acquisition Co. and each of the persons set forth on Schedule A thereto. EX-99.1 Exhibit 99.1 EXECUTION VERSION TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this ?Agreement?), dated as of December 23, 2017, is entered into by and among Mallinckrodt plc, an Irish public limited company (?Parent?), Sun Acquisition Co., a Delaware corporation and an indirect wholly owned subsidiary of Parent (?Purchaser?), and each of the persons set forth on Schedule A
December 26, 2017	EX-99.2	Press Release, dated December 26, 2017. EX-99.2 Exhibit 99.2 MALLINCKRODT TO ACQUIRE SUCAMPO PHARMACEUTICALS FOR APPROXIMATELY $1.2 BILLION Immediately accretive transaction includes development and commercial assets including AMITIZA® (lubiprostone), a leading product in branded constipation market Mallinckrodt expects accretion to 2018 adjusted diluted earnings per share of at least $0.30; and at least double that in 2019, assum
December 14, 2017	SC 13G	SCMP / Sucampo Pharmaceuticals, Inc. / ING GROEP NV - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 864909106 (CUSIP Number) December 7, 2017 (Date of Event Which Requires Fili
December 8, 2017	EX-99.A	JOINT FILING AGREEMENT EX-A Page 10 of 11 EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Shares of Sucampo Pharmaceuticals, Inc.
December 8, 2017	EX-99.B	IDENTIFICATION OF MEMBERS OF THE GROUP EX-B Page 11 of 11 EXHIBIT B IDENTIFICATION OF MEMBERS OF THE GROUP Linden Capital L.P. Linden Advisors LP Linden GP LLC Siu Min Wong
December 8, 2017	SC 13G	SCMP / Sucampo Pharmaceuticals, Inc. / Linden Capital L.P. - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) December 6, 201
November 16, 2017	EX-99.1	99.1 Presentation entitled “Sucampo 2017 R&D Day”, dated November 16, 2017 Exhibit 99.1
November 16, 2017	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2017 Sucampo Pharmaceuticals, Inc.
November 2, 2017	8-K/A	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2017 Sucampo Pharmaceuticals, Inc.
November 2, 2017	EX-99.1	Sucampo Reports Third Quarter 2017 Financial Results Company Increases 2017 Financial Guidance Based on Strong Performance Year to Date Study Results for VTS-270 for Niemann-Pick Disease Type C1 Published in The Lancet CPP-1X/sulindac Granted Fast-Tr Exhibit 99.1 Sucampo Reports Third Quarter 2017 Financial Results Company Increases 2017 Financial Guidance Based on Strong Performance Year to Date Study Results for VTS-270 for Niemann-Pick Disease Type C1 Published in The Lancet CPP-1X/sulindac Granted Fast-Track status by FDA for Adults with Familial Adenomatous Polyposis FDA Accepted sNDA for AMITIZA for Pediatric Functional Constipation in C
November 1, 2017	EX-99.2	November 1, 2017 Third Quarter 2017 Corporate Update and Financial Results 1 Introductions and Forward - Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs 2 Agenda Introductions and Forward - Looking Statements Silvia Taylo
November 1, 2017	EX-99.1	Sucampo Reports Third Quarter 2017 Financial Results Company Increases 2017 Financial Guidance Based on Strong Performance Year to Date Study Results for VTS-270 for Niemann-Pick Disease Type C1 Published in The Lancet CPP-1X/sulindac Granted Fast-Tr EdgarFiling EXHIBIT 99.1 Sucampo Reports Third Quarter 2017 Financial Results Company Increases 2017 Financial Guidance Based on Strong Performance Year to Date Study Results for VTS-270 for Niemann-Pick Disease Type C1 Published in The Lancet CPP-1X/sulindac Granted Fast-Track status by FDA for Adults with Familial Adenomatous Polyposis FDA Accepted sNDA for AMITIZA for Pediatric Functional Const
November 1, 2017	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2017 Sucampo Pharmaceuticals, Inc.
November 1, 2017	10-Q	SCMP / Sucampo Pharmaceuticals, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33609 SUCAM
November 1, 2017	EX-12.1	EX-12.1 Exhibit 12.1 Ratio of Earnings to Fixed Charges Nine Months Ended September 30, Year ended December 31, (in thousands, except for ratio) 2017 2016 2015 2014 2013 2012 Pretax income from continuing operations $ (166,175 ) $ 14,375 $ 43,675 $ 27,133 $ 10,943 $ 7,977 Fixed charges: Interest expense 8,762 23,761 6,854 1,520 1,894 2,346 Earnings (a) (157,413 ) 38,136 50,529 28,653 12,837 10,323 Fixed c
November 1, 2017	EX-10.1	SECOND AMENDMENT TO OFFICE LEASE AGREEMENT Exhibit 10.1 SECOND AMENDMENT TO OFFICE LEASE AGREEMENT THIS SECOND AMENDMENT TO OFFICE LEASE AGREEMENT (this “Second Amendment”) is made this day of , 2017 (the “Effective Date”), by and between FOUR IRVINGTON CENTRE ASSOCIATES, LLC, a Maryland limited liability company (“Landlord”), and SUCAMPO PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). W I T N E S S E T H : WHEREAS, pursuant to t
October 23, 2017	8-K/A	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2017 Sucampo Pharmaceuticals, Inc.
September 28, 2017	SC 13D/A	SCMP / Sucampo Pharmaceuticals, Inc. / Sachiko Kuno Foundation, Inc. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) David N. Oakey, Esquire McGuireWoods LLP 800 East Canal Street Richmond, VA 23219 (804) 775-1022 (Name,
September 28, 2017	SC 13D/A	SCMP / Sucampo Pharmaceuticals, Inc. / Ueno Ryuji - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) David N. Oakey, Esquire McGuireWoods LLP 800 East Canal Street Richmond, VA 23219 (804) 775-1022 (Name,
September 28, 2017	SC 13D/A	SCMP / Sucampo Pharmaceuticals, Inc. / Kuno Sachiko - SC 13D/A Activist Investment SC 13D/A 1 d460398dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) David N. Oakey, Esquire McGuireWoods LLP 800 East Canal Street Richmond, V
September 26, 2017	EX-99.1	Sucampo Pharmaceuticals, Inc. Emerging Specialized Disease Company Cantor Fitzgerald Global Healthcare Conference September 26, 2017 Forward Looking Statement This presentation contains "forward - looking statements" as that term is defined in the Pr Exhibit 99.1 Sucampo Pharmaceuticals, Inc. Emerging Specialized Disease Company Cantor Fitzgerald Global Healthcare Conference September 26, 2017 Forward Looking Statement This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and unc
September 26, 2017	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 f8k092617.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2017 Sucampo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33609 30-0520478 (State or other jurisd
September 20, 2017	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 7, 2017 Sucampo Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33609 30-0520478 (State or Other Jurisdiction of Incorporation) (Commis
September 20, 2017	EX-99.1	Sucampo Pharmaceuticals Appoints Alex Driggs as General Counsel EdgarFiling
September 8, 2017	8-K	Entry into a Material Definitive Agreement 8-K 1 f8k090817.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2017 Sucampo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33609 30-0520478 (State or other jurisdi
August 2, 2017	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2017 Sucampo Pharmaceuticals, Inc.
August 2, 2017	EX-99.2	August 2, 2017 Second Quarter 2017 Corporate Update and Financial Results 1 Introductions and Forward - Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs 2 Agenda Introductions and Forward - Looking Statements Silvia Taylor Exhibit 99.2 August 2, 2017 Second Quarter 2017 Corporate Update and Financial Results 1 Introductions and Forward - Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs 2 Agenda Introductions and Forward - Looking Statements Silvia Taylor Corporate Update Peter Greenleaf Pipeline Update Peter Kiener, D. Phil Financial Update Peter Pfreundschuh Closing Remarks Peter Greenle
August 2, 2017	EX-99.1	Sucampo Reports Second Quarter 2017 Financial Results Patent Issued for Pipeline Compound VTS-270 for Niemann-Pick Disease Type C1 Diluted EPS Loss of $3.92 Resulting from $186.6M IP R&D Second Quarter Charge Due to Accounting Treatment of Vtesse Inc EdgarFiling EXHIBIT 99.1 Sucampo Reports Second Quarter 2017 Financial Results Patent Issued for Pipeline Compound VTS-270 for Niemann-Pick Disease Type C1 Diluted EPS Loss of $3.92 Resulting from $186.6M IP R&D Second Quarter Charge Due to Accounting Treatment of Vtesse Inc. Acquisition; EPS were $0.28 on an Adjusted Diluted Basis Excluding IP R&D Charge and Other Adjustments* CPP-1X/Sulindac Pha
August 2, 2017	EX-10.2	SEPARATION AGREEMENT AND RELEASES Exhibit 10.2 SEPARATION AGREEMENT AND RELEASES This Separation Agreement and Releases ("Separation Agreement") is made and entered into as of June 6, 2017, by and between Matthias Alder (hereinafter "Executive") and Sucampo Pharmaceuticals, Inc. ("SPI"), a corporation organized under the laws of the State of Delaware, and its affiliates (hereinafter collectively referred to as the "Company"). WHER
August 2, 2017	10-Q	SCMP / Sucampo Pharmaceuticals, Inc. FORM 10-Q (Quarterly Report) 10-Q 1 f10q080217p.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission
August 2, 2017	EX-10.1	GENERAL RELEASE Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (the “Separation Agreement”) is made by and between Sucampo Pharmaceuticals, Inc., (“SPI”) and Andrew Smith (“Employee”). WHEREAS, Employee and SPI are parties to the Amended and Restated Executive Employment Agreement attached as Exhibit 1 to this Separation Agreement (“Employment Agre
August 2, 2017	EX-12.1	EX-12.1 Exhibit 12.1 Ratio of Earnings to Fixed Charges Six Months Ended June 30, Year ended December 31, (in thousands, except for ratio) 2017 2016 2015 2014 2013 2012 Pretax income from continuing operations $ (171,018 ) $ 14,375 $ 43,675 $ 27,133 $ 10,943 $ 7,977 Fixed charges: Interest expense 5,806 23,761 6,854 1,520 1,894 2,346 Earnings (a) (165,212 ) 38,136 50,529 28,653 12,837 10,323 Fixed charges
August 2, 2017	EX-10.3	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.3 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made by and between Sucampo Pharmaceuticals, Inc., its parent, subsidiary, predecessor and affiliated corporations (collectively “Sucampo”), and Jones Woodrow Bryan, Jr. (“Executive”). A. Employment and Duties. 1. Sucampo shall employ Executive as Senior Vice President, Business Development. While
July 27, 2017	EX-24	POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Exhibit 24 POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents that the undersigned hereby constitutes and appoints Tim Stover, Director, Financial Reporting, or delegate, signing individually, the undersigned?s true and lawful attorneys-in fact and agents to: (1) Prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the Sec
July 19, 2017	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 15, 2017 Sucampo Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33609 30-0520478 (State or Other Jurisdiction of Incorporation) (Commission
July 19, 2017	EX-99.1	Dr. Karen Smith Joins Sucampo’s Board of Directors EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Dr. Karen Smith Joins Sucampo’s Board of Directors ROCKVILLE, Md., July 18, 2017 (GLOBE NEWSWIRE) - Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that Karen Smith, M.D., Ph.D., M.B.A., LLM., has joined the Company’s Board of Directors on July 15. Dr. Smith is Executive Vice President, R&D,
June 20, 2017	CORRESP	SCMP / Sucampo Pharmaceuticals, Inc. ESP Sucampo Pharmaceuticals, Inc. 805 King Farm Boulevard, Suite 550 Rockville, MD 20850 June 20, 2017 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Gabor Re: Sucampo Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-218639 Acceleration Request Requested Date: Thursday, June 22, 2017 Request
June 20, 2017	CORRESP	SCMP / Sucampo Pharmaceuticals, Inc. ESP CORRESP 1 filename1.htm Sucampo Pharmaceuticals, Inc. 805 King Farm Boulevard, Suite 550 Rockville, MD 20850 June 20, 2017 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Gabor Re: Sucampo Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-218641 Acceleration Request Requested Date: Thursda
June 19, 2017	LETTER	LETTER June 19, 2017 Peter Greenleaf Chief Executive Officer Sucampo Pharmaceuticals, Inc.
June 19, 2017	LETTER	LETTER June 19, 2017 Peter Greenleaf Chief Executive Officer Sucampo Pharmaceuticals, Inc.
June 14, 2017	EX-24	POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Exhibit 24 POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents that the undersigned hereby constitutes and appoints Tim Stover, Director, Financial Reporting, or delegate, signing individually, the undersigned?s true and lawful attorneys-in fact and agents to: (1) Prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the Sec
June 12, 2017	EX-24	POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Exhibit 24 POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents that the undersigned hereby constitutes and appoints Tim Stover, Director, Financial Reporting, or delegate, signing individually, the undersigned?s true and lawful attorneys-in fact and agents to: (1) Prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the Sec
June 12, 2017	EX-24	POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Exhibit 24 POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents that the undersigned hereby constitutes and appoints Tim Stover, Director, Financial Reporting, or delegate, signing individually, the undersigned?s true and lawful attorneys-in fact and agents to: (1) Prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the Sec
June 9, 2017	S-3	Sucampo Pharmaceuticals FORM S-3 As filed with the Securities and Exchange Commission on June 9, 2017 Registration No.
June 9, 2017	EX-4.6	SUCAMPO PHARMACEUTICALS, INC. ________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ______________ SUCAMPO PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT EXHIBIT 4.6 SUCAMPO PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF SUCAMPO PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT Debt Securities Warrant Agreement (this “Agreement”), dated as of between Sucampo Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized an
June 9, 2017	EX-4.4	SUCAMPO PHARMACEUTICALS, INC. ________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF _____________ SUCAMPO PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT EXHIBIT 4.4 SUCAMPO PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF SUCAMPO PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT Common Stock Warrant Agreement (this “Agreement”), dated as of between Sucampo Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existin
June 9, 2017	S-3	As filed with the Securities and Exchange Commission on June 9, 2017 As filed with the Securities and Exchange Commission on June 9, 2017 Registration No.
June 9, 2017	EX-4.2	Sucampo Pharmaceuticals, INC., Issuer AND [TRUSTEE], Trustee Dated as of ______________ Debt Securities Table Of Contents Exhibit 4.2 Sucampo Pharmaceuticals, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of Debt Securities Table Of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Secti
June 9, 2017	EX-4.5	sucampo pharmaceuticals, INC. ________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ___________ SUCAMPO PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT EXHIBIT 4.5 sucampo pharmaceuticals, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF SUCAMPO PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT Preferred Stock Warrant Agreement (this “Agreement”), dated as of between Sucampo Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized an
June 6, 2017	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2017 Sucampo Pharmaceuticals, Inc.
June 1, 2017	CT ORDER	Sucampo Pharmaceuticals RDER UNITED STATES SECURITIES AND EXCHANGE COMMISSION June 1, 2017 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Sucampo Pharmaceuticals, Inc.
May 22, 2017	EX-99.3	UNAUDITED PRO FORMA COMBINED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.3 UNAUDITED PRO FORMA COMBINED CONSOLIDATED FINANCIAL STATEMENTS On March 31, 2017, Sucampo Pharmaceuticals, Inc. (the ?Company?) entered into a merger agreement (the ?Merger Agreement?) with Vtesse, Inc. (?Vtesse?), and on April 3, 2017, the Company completed the transactions contemplated by the Merger Agreement (the ?Merger?), for an initial purchase price of $200.0 million. The initi
May 22, 2017	EX-99.2	Vtesse, Inc. Balance Sheets Exhibit 99.2 Vtesse, Inc. Balance Sheets March 31, December 31, 2017 (Unaudited) 2016 Assets Current assets: Cash $ 12,330,829 $ 14,369,690 Prepaid expenses and other current assets 443,996 155,995 Total current assets 12,774,825 14,525,685 Property and equipment, net 27,393 42,895 Intangibles, net 64,885 70,249 Escrows and other deposits 107,700 106,150 Total assets $ 12,974,803 $ 14,744,979 Liab
May 22, 2017	8-K/A	Sucampo Pharmaceuticals FORM 8-K/A (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
May 22, 2017	EX-99.1	Vtesse, Inc. Financial Statements Years Ended December 31, 2016 and 2015 EX-99.1 3 exh991.htm EXHIBIT 99.1 Exhibit 99.1 Financial Statements Vtesse, Inc. Years Ended December 31, 2016 and 2015 With Report of Independent Auditors Vtesse, Inc. Financial Statements Years Ended December 31, 2016 and 2015 Contents Report of Independent Auditors 1 Financial Statements Balance Sheets 3 Statements of Operations and Comprehensive Loss 4 Statements of Changes in Stockholders’ Eq
May 3, 2017	EX-2.1	Agreement and Plan of Merger, dated March 31, 2017, among the Company, Saber Merger Sub, Inc., Vtesse Inc. and Fortis Advisors, LLC solely in its capacity as Vtesse Inc. equityholder representative EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGER by and among Sucampo pharmaceuticals, inc., SABER MERGER SUB, INC., VTESSE INC. and, SOLELY IN ITS CAPACITY as COMPANY EQUITYHOLDER REPRESENTATIVE, Fortis Advisors LLC Dated as of MARCH 31, 2017 Confidential and Proprietary CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONF
May 3, 2017	10-Q	Sucampo Pharmaceuticals FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33609 SUCAMPO P
May 3, 2017	EX-99.1	Sucampo Reports First Quarter 2017 Financial Results Continued Revenue Growth Recent Vtesse Acquisition Bolsters Pipeline Company Reiterates 2017 Guidance Company to Host Conference Call Today at 8:30 a.m. EDT EdgarFiling EXHIBIT 99.1 Sucampo Reports First Quarter 2017 Financial Results Continued Revenue Growth Recent Vtesse Acquisition Bolsters Pipeline Company Reiterates 2017 Guidance Company to Host Conference Call Today at 8:30 a.m. EDT ROCKVILLE, Md., May 03, 2017 (GLOBE NEWSWIRE) - Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today reported consolidate
May 3, 2017	EX-99.2	First Quarter 2017 Corporate Update and Financial Results May 3, 2017 1 Introductions and Forward - Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs Agenda Introductions and Forward - Looking Statements Silvia Taylor Corpo EXHIBIT 99.2 First Quarter 2017 Corporate Update and Financial Results May 3, 2017 1 Introductions and Forward - Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs Agenda Introductions and Forward - Looking Statements Silvia Taylor Corporate Update Peter Greenleaf Pipeline Update Peter Kiener , D. Phil Financial Update Peter Pfreundschuh Closing Remarks Peter Greenleaf 3
May 3, 2017	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2017 Sucampo Pharmaceuticals, Inc.
May 3, 2017	EX-12.1	Ratio of earnings to fixed charges Exhibit 12.1 Ratio of Earnings to Fixed Charges Year to date March 31, Year ended December 31, (in thousands, except for ratio) 2017 2016 2015 2014 2013 2012 Pretax income from continuing operations $ 8,209 $ 14,375 $ 43,675 $ 27,133 $ 10,943 $ 7,977 Fixed charges: Interest expense 2,890 23,761 6,854 1,520 1,894 2,346 Earnings (a) 11,099 38,136 50,529 28,653 12,837 10,323 Fixed charges (b) 2,890 2
May 3, 2017	EX-10.1	Employment Agreement, dated as of March 20, 2017, between the Company and Peter Pfreundschuh Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made by and between Sucampo Pharmaceuticals, Inc., its parent, subsidiary, predecessor and affiliated corporations (collectively “Sucampo”), and Peter Pfreundschuh (“Executive”). A. Employment and Duties. 1. Sucampo shall employ Executive as Chief Financial Officer. While employed by Sucampo, Execu
April 21, 2017	DEF 14A	Sucampo Pharmaceuticals DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X]
April 3, 2017	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2017 Sucampo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33609 30-0520478 (Commi
April 3, 2017	EX-99.1	Sucampo Acquires Vtesse Inc. Transaction Valued at $200 Million Upfront Diversifies Pipeline with Late Stage Program in Niemann-Pick Disease Type C1 (NPC-1) Increases Company Focus on Specialized Diseases with High Unmet Need Leverages Focus on Orpha EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 Sucampo Acquires Vtesse Inc. Transaction Valued at $200 Million Upfront Diversifies Pipeline with Late Stage Program in Niemann-Pick Disease Type C1 (NPC-1) Increases Company Focus on Specialized Diseases with High Unmet Need Leverages Focus on Orphan and Pediatric Diseases Expected to be Accretive to Earnings Beginning in 2019 Shareholders and Invest
April 3, 2017	EX-99.2	Acquisition of Vtesse Inc. Increased Focus on Orphan and Pediatric Diseases 1 Forward Looking Statement This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These i Exhibit 99.2 Acquisition of Vtesse Inc. Increased Focus on Orphan and Pediatric Diseases 1 Forward Looking Statement This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These include statements about the development and potential commercialization of VTS - 270, the timing of expected clinical trial results, the
March 22, 2017	EX-24	POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Exhibit 24 POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents that the undersigned hereby constitutes and appoints Charles McFalls, Financial Reporting Manager, or delegate, signing individually, the undersigned?s true and lawful attorneys-in fact and agents to: (1) Prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the
March 13, 2017	EX-99.1	29 th Annual ROTH Conference March 13, 2017 Sucampo Pharmaceuticals, Inc. Corporate Update Forward Looking Statements This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of Exhibit 99.1 29 th Annual ROTH Conference March 13, 2017 Sucampo Pharmaceuticals, Inc. Corporate Update Forward Looking Statements This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to di
March 13, 2017	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2017 Sucampo Pharmaceuticals, Inc.
March 8, 2017	10-K	Sucampo Pharmaceuticals FORM 10-K (Annual Report) 10-K 1 f10k030817p.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File
March 8, 2017	EX-99.1	Sucampo Reports Fourth Quarter and Full Year 2016 Financial Results Continued Revenue Growth Leads to Strong Income Growth Company Reiterates 2017 Guidance Company Announces Key Executive Transitions Company to Host Conference Call Today at 8:30 a.m. EdgarFiling EXHIBIT 99.1 Sucampo Reports Fourth Quarter and Full Year 2016 Financial Results Continued Revenue Growth Leads to Strong Income Growth Company Reiterates 2017 Guidance Company Announces Key Executive Transitions Company to Host Conference Call Today at 8:30 a.m. EST ROCKVILLE, Md., March 08, 2017 (GLOBE NEWSWIRE) - Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopha
March 8, 2017	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K 1 f8k030817.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2017 Sucampo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33609 30-0520478 (State or other jurisdictio
March 8, 2017	EX-99.2	March 8, 2017 Fourth Quarter 2016 Corporate Update and Financial Results Introductions and Forward - Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs Agenda Introductions and Forward - Looking Statements Silvia Taylor Corp EXHIBIT 99.2 March 8, 2017 Fourth Quarter 2016 Corporate Update and Financial Results Introductions and Forward - Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs Agenda Introductions and Forward - Looking Statements Silvia Taylor Corporate Update Peter Greenleaf Pipeline Update Peter Kiener , D. Phil Financial Update Andrew Smith Closing Remarks Peter Greenleaf 3 Forwa
March 8, 2017	EX-21	SUBSIDIARIES OF COMPANY Exhibit 21 SUBSIDIARIES OF COMPANY Subsidiary State or other jurisdiction of incorporation or organization Sucampo Pharma Americas, LLC Delaware Sucampo LLC Delaware Sucampo AG Switzerland Sucampo Pharma, LLC Japan Sucampo Pharma Europe Ltd. United Kingdom Sucampo Acquisitions GmbH Switzerland
March 8, 2017	EX-12.1	EX-12.1 Exhibit 12.1 Ratio of Earnings to Fixed Charges Year ended December 31, (in thousands, except for ratio) 2016 2015 2014 2013 2012 Pretax income from continuing operations $ 14,375 $ 43,675 $ 27,133 $ 10,943 $ 7,977 Fixed charges: Interest expense 23,761 6,854 1,520 1,894 2,346 Earnings (a) 38,136 50,529 28,653 12,837 10,323 Fixed charges (b) 23,761 6,854 1,520 1,894 2,346 Ratio of earnings to fixe
March 8, 2017	EX-10.44	SUCAMPO PHARMACEUTICALS, INC. AMENDED AND RESTATED 2006 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 5, 2006 APPROVED BY THE STOCKHOLDERS: SEPTEMBER 5, 2006 AMENDMENT AND RESTATEMENT APPROVED BY THE BOARD: DECEMBER 8, 2016 Exhibit 10.44 SUCAMPO PHARMACEUTICALS, INC. AMENDED AND RESTATED 2006 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 5, 2006 APPROVED BY THE STOCKHOLDERS: SEPTEMBER 5, 2006 AMENDMENT AND RESTATEMENT APPROVED BY THE BOARD: DECEMBER 8, 2016 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations m
March 8, 2017	EX-10.45	Sucampo Pharmaceuticals, Inc. 2016 Equity Incentive Plan Employee Restricted Stock Unit Award Grant Notice Exhibit 10.45 Sucampo Pharmaceuticals, Inc. 2016 Equity Incentive Plan Employee Restricted Stock Unit Award Grant Notice Sucampo Pharmaceuticals, Inc. (the “Company”) hereby grants to Participant a Restricted Stock Unit Award (the “Award”) under the Sucampo Pharmaceuticals, Inc. 2016 Equity Incentive Plan (the “Plan”) for the number of restricted stock units (the “RSUs”) set forth below. This Awar
February 14, 2017	SC 13G/A	SCMP / Sucampo Pharmaceuticals, Inc. / S&R Technology Holdings, LLC - SC 13G AMENDMENT NO. 8 Passive Investment SC 13G/A 1 d347688dsc13ga.htm SC 13G AMENDMENT NO. 8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Amendment No. 8 SUCAMPO PHARMACEUTICALS, INC. (Name of Issuer) CLASS A COMMON STOCK (Title of Class of Securities) 864909106 (CUSIP Number) DECEMBER 31, 2016 (Date of Event Which Requires Filing of this Statement) Chec
February 13, 2017	LETTER	LETTER Mail Stop 4546 February 10, 2017 Mr. Andrew P. Smith Chief Financial Officer Sucampo Pharmaceuticals, Inc. 805 King Farm Boulevard Suite 550 Rockville, MD 20850 Re: Sucampo Pharmaceuticals, Inc. Form 8-K dated November 9, 2016 Filed November 9, 2016 File No. 1-33609 Dear Mr. Smith: We have completed our review of your filings. We remind you that the company and its management are responsible for t
February 8, 2017	SC 13G/A	SCMP / Sucampo Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) SUCAMPO PHARMACEUTICALS INC - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 864909106 - (CUSIP Number) January 31, 2016 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 30, 2017	SC 13G	Sucampo Pharmaceuticals 3G (Passive Acquisition of More Than 5% of Shares) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) SUCAMPO PHARMACEUTICALS INC - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 864909106 - (CUSIP Number) December 31, 2016 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 9, 2017	EX-99.1	January 2017 Sucampo Pharmaceuticals, Inc. Corporate Update Non - GAAP Metrics 3 This presentation contains three financial metrics (Adjusted Net Income, EBITDA and Adjusted EBITDA) that are considered “non - GAAP” financial metrics under applicable Exhibit 99.1 January 2017 Sucampo Pharmaceuticals, Inc. Corporate Update Forward Looking Statements This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set
January 9, 2017	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 f8k010917.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2017 Sucampo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33609 30-0520478 (State or other jurisdict
January 5, 2017	CORRESP	Sucampo Pharmaceuticals ESP January 5, 2017 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Mr. Jim B. Rosenberg Ms. Lisa Vanjoske RE: Sucampo Pharmaceuticals, Inc. Form 8-K dated November 9, 2016 Filed November 9, 2016 File No. 1-33609 Ladies and Gentlemen: We are responding to comments received from the staff of the Division of
December 29, 2016	SC 13D	SCMP / Sucampo Pharmaceuticals, Inc. / Ueno Ryuji - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) David N. Oakey, Esquire McGuireWoods LLP 800 East Canal Street Richmond, VA 23219 (804) 775-1022 (Name, Address and Telephone
December 29, 2016	EX-99.1	Joint Filing Agreement EX-99.1 Exhibit 1.1 Joint Filing Agreement The undersigned parties hereby agree to the joint filing of the Statement on Schedule 13D filed herewith, and any amendments thereto, relating to the shares of Class A Common Stock, par value $0.01 per share, of Sucampo Pharmaceuticals, Inc. with the Securities and Exchange Commission pursuant to Rule 13d-1(k). Dated: December 28, 2016 /s/ Ryuji Ueno Ryuj
December 29, 2016	SC 13D	SCMP / Sucampo Pharmaceuticals, Inc. / Kuno Sachiko - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) David N. Oakey, Esquire McGuireWoods LLP 800 East Canal Street Richmond, VA 23219 (804) 775-1022 (Name, Address and Telephone
December 29, 2016	SC 13D	Sucampo Pharmaceuticals SC 13D (Activist Acquisition of More Than 5% of Shares) SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) David N. Oakey, Esquire McGuireWoods LLP 800 East Canal Street Richmond, VA 23219 (804) 775-1022 (Name, Address and Telephone
December 29, 2016	EX-99.1	Joint Filing Agreement EX-99.1 Exhibit 1.1 Joint Filing Agreement The undersigned parties hereby agree to the joint filing of the Statement on Schedule 13D filed herewith, and any amendments thereto, relating to the shares of Class A Common Stock, par value $0.01 per share, of Sucampo Pharmaceuticals, Inc. with the Securities and Exchange Commission pursuant to Rule 13d-1(k). Dated: December 28, 2016 /s/ Sachiko Kuno Sa
December 29, 2016	SC 13D/A	SCMP / Sucampo Pharmaceuticals, Inc. / S&R Foundation - SC 13D AMENDMENT NO. 1 Activist Investment SC 13D Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) David N. Oakey, Esquire McGuireWoods LLP 800 East Canal Street Richmond, VA 23219 (804) 775
December 28, 2016	LETTER	LETTER Mail Stop 4546 December 28, 2016 Mr. Andrew P. Smith Chief Financial Officer Sucampo Pharmaceuticals, Inc. 805 King Farm Boulevard Suite 550 Rockville, MD 20850 Re: Sucampo Pharmaceuticals, Inc. Form 8-K dated November 9, 2016 Filed November 9, 2016 File No. 1-33609 Dear Mr. Smith: We have limited our review of your filing to those issues we have addressed in our comments. In some of our comments,
December 27, 2016	EX-4.1	Indenture, dated as of December 27, 2016, between Sucampo Pharmaceuticals, Inc. and U.S. Bank National Association, as Trustee (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC by Sucampo Pharmaceuticals, Inc. on December 27, 2016). EX-4.1 Exhibit 4.1 EXECUTION VERSION SUCAMPO PHARMACEUTICALS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of December 27, 2016 3.25% Convertible Senior Notes due 2021 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 10 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Des
December 27, 2016	EX-99.1	Sucampo Announces Pricing of $260.0 Million 3.25% Convertible Senior Notes due 2021 EX-99.1 3 d282681dex991.htm EX-99.1 Exhibit 99.1 Sucampo Announces Pricing of $260.0 Million 3.25% Convertible Senior Notes due 2021 ROCKVILLE, MD, December 21, 2016 (GLOBE NEWSWIRE) - Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a global biopharmaceutical company, today announced the December 20, 2016 pricing of $260.0 million aggregate principal amount of 3.25% convertible senior notes due 2021
December 27, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events 8-K 1 d282681d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2016 Sucampo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpora
December 19, 2016	EX-99.2	December 2016 Sucampo Pharmaceuticals, Inc. Corporate Update Additional Disclosures and Non - GAAP Financial Measures Sucampo has prepared an offering memorandum for the offering to which this presentation relates. Before you invest, you should read Exhibit 99.2 December 2016 Sucampo Pharmaceuticals, Inc. Corporate Update Forward Looking Statements This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set
December 19, 2016	EX-99.1	Sucampo Announces Proposed Convertible Senior Note Offering EdgarFiling EXHIBIT 99.1 Sucampo Announces Proposed Convertible Senior Note Offering ROCKVILLE, Md., Dec. 19, 2016 (GLOBE NEWSWIRE) - Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), a global biopharmaceutical company, today announced its intention to offer, subject to market and other conditions, $225.0 million principal amount of convertible senior notes due 2021 (the ?notes?) in a private offering
December 19, 2016	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2016 Sucampo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33609 30-0520478 (Co
November 9, 2016	EX-10.1	INDEMNIFICATION AGREEMENT Exhibit 10.1 INDEMNIFICATION AGREEMENT INDEMNIFICATION AGREEMENT (this ?Agreement?) dated as of July [], 2016 by and between Sucampo Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, and [](?Indemnitee?): WHEREAS, competent persons are reluctant to serve a corporation as an officer or in another capacity unless they are provided with adequate protection through insurance or adequate i
November 9, 2016	EX-10.3	AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.3 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?) is made by and between Sucampo Pharmaceuticals, Inc., its parent, subsidiary, predecessor and affiliated corporations (collectively ?Sucampo?), and Peter Kiener (?Executive?), and amends, restates and supersedes the Employment Agreement between Sucampo and Exe
November 9, 2016	10-Q	Sucampo Pharmaceuticals FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33609 SUCAM
November 9, 2016	EX-10.2	AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.2 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?) is made by and between Sucampo Pharmaceuticals, Inc., its parent, subsidiary, predecessor and affiliated corporations (collectively ?Sucampo?), and Peter Greenleaf (?Executive?), and amends, restates and supersedes the Employment Agreement between Sucampo and
November 9, 2016	EX-10.4	AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.4 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is made by and between Sucampo Pharmaceuticals, Inc., its parent, subsidiary, predecessor and affiliated corporations (collectively “Sucampo”), and Andrew Smith (“Executive”), and amends, restates and supersedes the Employment Agreement between Sucampo and Exe
November 9, 2016	EX-99.2	EX-99.2 EXHIBIT 99.2
November 9, 2016	EX-99.1	Sucampo Reports Third Quarter 2016 Financial Results Results Driven by 73% Growth in Revenue GAAP EPS Growth of 12%; Adjusted EPS Growth of 58% Company Raises 2016 Guidance and Provides Preliminary 2017 Guidance Announces Settlement with Dr. Reddy’s EdgarFiling EXHIBIT 99.1 Sucampo Reports Third Quarter 2016 Financial Results Results Driven by 73% Growth in Revenue GAAP EPS Growth of 12%; Adjusted EPS Growth of 58% Company Raises 2016 Guidance and Provides Preliminary 2017 Guidance Announces Settlement with Dr. Reddy’s Laboratories for AMITIZA Reports Phase Three Results for AMITIZA in Pediatric Population Company to Host Conference Call Toda
November 9, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2016 Sucampo Pharmaceuticals, Inc.
November 9, 2016	EX-10.5	AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT EX-10.5 6 exh105.htm EXHIBIT 10.5 Exhibit 10.5 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is made by and between Sucampo Pharmaceuticals, Inc., its parent, subsidiary, predecessor and affiliated corporations (collectively “Sucampo”), and Matthew Maxwell Donley (“Executive”), and amends, restates and supersedes the
November 9, 2016	EX-10.6	AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.6 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is made by and between Sucampo AG, Baarerstrasse 22, 6300 Zug, (“Sucampo”), and Peter Lichtlen (“Executive”), and amends, restates and supersedes the Employment Agreement between Sucampo and Executive dated October 21, 2014. A. Employment and Duties. 1. Sucamp
September 27, 2016	LETTER	LETTER Mail Stop 4546 September 27, 2016 Via E-mail Mr. Andrew P. Smith Chief Financial Officer Sucampo Pharmaceuticals, Inc. 805 King Farm Boulevard Suite 550 Rockville, MD 20850 Re: Sucampo Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2015 Filed March 11, 2016 File No. 1-33609 Dear Mr. Smith: We have completed our review of your filings. We remind you that our comments or chan
September 21, 2016	S-8	Sucampo Pharmaceuticals FORM S-8 S-8 1 fs8092016.htm FORM S-8 As filed with the Securities and Exchange Commission on September 21, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sucampo Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 30-0520478 (State or other jurisdiction of
September 21, 2016	EX-4.6	Sucampo Pharmaceuticals, Inc. Stock Option Grant Notice (2016 Equity Incentive Plan) Exhibit 4.6 Sucampo Pharmaceuticals, Inc. Stock Option Grant Notice (2016 Equity Incentive Plan) Sucampo Pharmaceuticals, Inc. (the ?Company?), pursuant to its 2016 Equity Incentive Plan (the ?Plan?), hereby grants to Optionholder an option to purchase the number of shares of the Company?s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this
September 21, 2016	EX-4.7	Sucampo Pharmaceuticals, Inc. 2016 Equity Incentive Plan Non-Employee Director Restricted Stock Unit Award Grant Notice Exhibit 4.7 Sucampo Pharmaceuticals, Inc. 2016 Equity Incentive Plan Non-Employee Director Restricted Stock Unit Award Grant Notice Sucampo Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Sucampo Pharmaceuticals, Inc. 2016 Equity Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below
September 12, 2016	CORRESP	Sucampo Pharmaceuticals ESP September 12, 2016 via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Mr. Jim B. Rosenberg Ms. Lisa Vanjoske RE: Sucampo Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2015 Filed March 11, 2016 File No. 1-33609 Ladies and Gentlemen: We are responding to a comment received from the
August 31, 2016	LETTER	LETTER Mail Stop 4546 August 31, 2016 Via E-mail Mr. Andrew P. Smith Chief Financial Officer Sucampo Pharmaceuticals, Inc. 805 King Farm Boulevard Suite 550 Rockville, MD 20850 Re: Sucampo Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2015 Filed March 11, 2016 File No. 1-33609 Dear Mr. Smith: We have reviewed your August 22, 2016 response to our comment letter and have the follow
August 26, 2016	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2016 Sucampo Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33609 30-0520478 (State or Other Jurisdiction of Incorporation) (Commissi
August 22, 2016	CORRESP	Sucampo Pharmaceuticals ESP August 22, 2016 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Mr. Jim B. Rosenberg Ms. Lisa Vanjoske RE: Sucampo Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2015 Filed March 11, 2016 Form 8-K dated August 3, 2016 Filed August 3, 2016 File No. 1-33609 Ladies and Gentlemen: We are resp
August 9, 2016	LETTER	LETTER Mail Stop 4546 August 9, 2016 Via E-mail Mr. Andrew P. Smith Chief Financial Officer Sucampo Pharmaceuticals, Inc. 805 King Farm Boulevard Suite 550 Rockville, MD 20850 Re: Sucampo Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2015 Filed March 11, 2016 Form 8-K dated August 3, 2016 Filed August 3, 2016 File No. 1-33609 Dear Mr. Smith: We have reviewed your filings and have
August 9, 2016	EX-24	POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Exhibit 24 POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents that the undersigned hereby constitutes and appoints Charles McFalls, Financial Reporting Manager, or delegate, signing individually, the undersigned?s true and lawful attorneys-in fact and agents to: (1) Prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the
August 8, 2016	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2016 Sucampo Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33609 30-0520478 (State or Other Jurisdiction of Incorporation) (Commissio
August 3, 2016	10-Q	Sucampo Pharmaceuticals FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33609 SUCAMPO PH
August 3, 2016	EX-10.1	SUCAMPO PHARMACEUTICALS, INC. 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 18, 2016 APPROVED BY THE STOCKHOLDERS: JUNE 2, 2016 TERMINATION DATE: APRIL 18, 2026 EXHIBIT 10.1 SUCAMPO PHARMACEUTICALS, INC. 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 18, 2016 APPROVED BY THE STOCKHOLDERS: JUNE 2, 2016 TERMINATION DATE: APRIL 18, 2026 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Sucampo Pharmaceuticals, Inc. 2006 Stock Incentive Plan, as amended (the ?Prio
August 3, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 f8k080316.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2016 Sucampo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33609 30-0520478 (State or other jurisdicti
August 3, 2016	EX-99.1	Sucampo Reports Second Quarter 2016 Financial Results Results Driven by 49% Growth in Revenue Adjusted EPS Growth of 10% Company Reiterates 2016 Guidance Company to Host Conference Call Today at 8:30 a.m. ET EdgarFiling EXHIBIT 99.1 Sucampo Reports Second Quarter 2016 Financial Results Results Driven by 49% Growth in Revenue Adjusted EPS Growth of 10% Company Reiterates 2016 Guidance Company to Host Conference Call Today at 8:30 a.m. ET ROCKVILLE, Md., Aug. 03, 2016 (GLOBE NEWSWIRE) - Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today reported consolidated
August 3, 2016	EX-99.2	EX-99.2 EXHIBIT 99.2
July 29, 2016	EX-99.1	Paul Edick Joins Sucampo’s Board of Directors EdgarFiling EXHIBIT 99.1 Paul Edick Joins Sucampo’s Board of Directors ROCKVILLE, Md., July 29, 2016 (GLOBE NEWSWIRE) - Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that Paul Edick will join Sucampo's Board of Directors on August 1. Mr. Edick is the former CEO of Durata Therapeutics and currently the founding partner of 3G Advisors. "I
July 29, 2016	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 25, 2016 Sucampo Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33609 30-0520478 (State or Other Jurisdiction of Incorporation) (Commission
July 12, 2016	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2016 Sucampo Pharmaceuticals, Inc.
July 12, 2016	EX-99.1	EX-99.1 EXHIBIT 99.1
July 11, 2016	EX-99.2	UNAUDITED PRO FORMA COMBINED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA COMBINED CONSOLIDATED FINANCIAL INFORMATION The following unaudited pro forma combined consolidated financial information is presented to illustrate the estimated effects of the acquisition of R-Tech Ueno, Ltd. (?R-Tech?) by Sucampo Pharmaceuticals, Inc. (?Sucampo?) and certain other adjustments listed below, which are collectively referred to as the acquisition ad
July 11, 2016	EX-99.1	- 3 - Exhibit 99.1 R-Tech Ueno, Ltd. Financial Statements for the Years Ended March 31, 2015, 2014 and 2013, and Independent Auditors' Report INDEPENDENT AUDITORS' REPORT To the Board of Directors and Shareholders of R-Tech Ueno, Ltd. Tokyo, Japan: We have audited the accompanying financial statements of R-Tech Ueno, Ltd. (the "Company"), which comprise the balance sheets as of March 31, 2015 and 2014 a
July 11, 2016	8-K/A	Sucampo Pharmaceuticals FORM 8-K/A (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
July 8, 2016	SC 13G/A	SCMP / Sucampo Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) SUCAMPO PHARMACEUTICALS, INC. - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 864909106 - (CUSIP Number) June 30, 2016 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t
June 28, 2016	8-K/A	Sucampo Pharmaceuticals FORM 8-K/A (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2015 Sucampo Pharmaceuticals, Inc.
June 28, 2016	EX-99.2	UNAUDITED PRO FORMA COMBINED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA COMBINED CONSOLIDATED FINANCIAL INFORMATION The following unaudited pro forma combined consolidated financial information is presented to illustrate the estimated effects of the proposed acquisition of R-Tech Ueno, Ltd. (?R-Tech?) by Sucampo Pharmaceuticals, Inc. (?Sucampo?) and certain other adjustments listed below, which are collectively referred to as the acqui
June 28, 2016	EX-99.1	- 3 - Exhibit 99.1 R-Tech Ueno, Ltd. Financial Statements for the Years Ended March 31, 2015, 2014 and 2013, and Independent Auditors' Report INDEPENDENT AUDITORS' REPORT To the Board of Directors and Shareholders of R-Tech Ueno, Ltd. Tokyo, Japan: We have audited the accompanying financial statements of R-Tech Ueno, Ltd. (the "Company"), which comprise the balance sheets as of March 31, 2015 and 2014 a
June 14, 2016	CT ORDER	Sucampo Pharmaceuticals RDER UNITED STATES SECURITIES AND EXCHANGE COMMISSION June 14, 2016 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Sucampo Pharmaceuticals, Inc.
June 8, 2016	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2016 Sucampo Pharmaceuticals, Inc.
May 24, 2016	CT ORDER	Sucampo Pharmaceuticals RDER UNITED STATES SECURITIES AND EXCHANGE COMMISSION May 24, 2016 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Sucampo Pharmaceuticals, Inc.
May 5, 2016	EX-10.4	SEPARATION AGREEMENT AND RELEASES Exhibit 10.4 SEPARATION AGREEMENT AND RELEASES This Separation Agreement and Releases (“Separation Agreement”) is made and entered into as of the 29th day of February, 2016, by and between Stanley Miele (hereinafter “Executive”) and Sucampo Pharmaceuticals, Inc. (“SPI”), a corporation organized under the laws of the State of Delaware, and its affiliates (hereinafter collectively referred to as the
May 5, 2016	EX-10.5	EMPLOYMENT AGREEMENT Exhibit 10.5 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the "Agreement"), dated as of January 30, 2015, is hereby entered into in the State of Maryland by and between SUCAMPO PHARMACEUTICALS, INC., a Delaware limited liability company (the "Company"), and Andrew Smith ("Executive"). WHEREAS, Executive was hired as the Chief Financial Officer of the Company as of January 30, 2015; WHEREAS, Exe
May 4, 2016	EX-10.1	CONVERTIBLE PROMISSORY NOTE EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 CONVERTIBLE PROMISSORY NOTE THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY OTHER STATE OR JURISDICTION. THEY MAY NOT BE PURCHASED WITH A VIEW FOR DISTRIBUTION OR RESALE, AND MAY ONLY BE OFFERED, SOLD, MORTGAGED, PLEDGED, H
May 4, 2016	EX-10.2	OPTION AND COLLABORATION AGREEMENT Exhibit 10.2 OPTION AND COLLABORATION AGREEMENT This Option and Collaboration Agreement (?Agreement?) dated 9th day of January, 2016 (?Effective Date?) by and between Cancer Prevention Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, having a place of business at 1760 East River Road, Suite 250, Tucson, Arizona 85718 (?CPP?), and Sucampo AG, a co
May 4, 2016	EX-10.3	SECURITIES PURCHASE AGREEMENT Exhibit 10.3 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of January 9, 2016 by and between Cancer Prevention Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Sucampo AG, a Swiss corporation, and a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc., a Delaware corporation (together, the ?Purchaser?). WHERE
May 4, 2016	10-Q	Sucampo Pharmaceuticals FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33609 SUCAMPO P
May 4, 2016	EX-99.2	EX-99.2
May 4, 2016	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2016 Sucampo Pharmaceuticals, Inc.
May 4, 2016	EX-99.1	Sucampo Reports Strong Results for First Quarter of 2016 Results Driven by 60% Growth in Revenue Company Reiterates 2016 Guidance Company to Host Conference Call Today at 8:30 a.m. EDT EdgarFiling EXHIBIT 99.1 Sucampo Reports Strong Results for First Quarter of 2016 Results Driven by 60% Growth in Revenue Company Reiterates 2016 Guidance Company to Host Conference Call Today at 8:30 a.m. EDT ROCKVILLE, Md., May 04, 2016 (GLOBE NEWSWIRE) - Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today reported consolidated financial results for t
April 18, 2016	DEF 14A	Sucampo Pharmaceuticals DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X]
March 16, 2016	10-K/A	Sucampo Pharmaceuticals FORM 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-3
March 11, 2016	10-K	Sucampo Pharmaceuticals FORM 10-K (Annual Report) 10-K 1 f10k030816p.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File
March 11, 2016	EX-10.36	Sucampo Pharmaceuticals, Inc. Duration-Based Stock Option Incentive Award Stock Option Agreement Terms and Conditions Exhibit 10.36 Sucampo Pharmaceuticals, Inc. Duration-Based Stock Option Incentive Award Stock Option Agreement Terms and Conditions This Incentive Stock Option Agreement, along with the Sucampo Pharmaceuticals, Inc. Duration -Based Stock Option Incentive Award Summary delivered herewith (the "Award Summary"), once signed by the individual named on the Award Summary (the "Participant"), shall const
March 11, 2016	EX-10.35	Sucampo Pharmaceuticals, Inc. Non-Employee Director Compensation Summary Exhibit 10.35 Sucampo Pharmaceuticals, Inc. Non-Employee Director Compensation Summary This summary applies to each director of Sucampo Pharmaceuticals, Inc. (the “Company”) who is not a Company employee (a “Non-Employee Director”). Directors who are employed by the Company do not receive additional compensation for their service on the Board or its Committees. Each Non-Employee Director receives
March 11, 2016	EX-10.37	AMENDMENT 1 TO THE LICENSE, DEVELOPMENT, COMMERCIALIZATION AND SUPPLY AGREEMENT FOR LUBIPROSTONE EX-10.37 4 exh1037.htm EXHIBIT 10.37 Exhibit 10.37 AMENDMENT 1 TO THE LICENSE, DEVELOPMENT, COMMERCIALIZATION AND SUPPLY AGREEMENT FOR LUBIPROSTONE This Amendment 1 is entered into as of 18 November 2015 (the “Effective Date”) by and between Sucampo AG, a corporation organized under the laws of Switzerland with principal offices at Baarerstrasse 22, CH-6300, Zug, Switzerland (“Sucampo”) and Takeda
March 11, 2016	EX-10.39	Confidential and Proprietary Exhibit 10.39 Ground Lease Agreement UENO FINE CHEMICALS INDUSTRY LTD. (hereinafter, “Party A”), and R-Tech Ueno, Ltd. (hereinafter, “Party B”) form the following agreement regarding the ground lease of the land owned by Party A which is described at the end of the document (hereinafter, “This Land”). Article 1 (Purpose of Use) Party A agrees to lease This Land in order for Party B to have ownersh
March 11, 2016	EX-10.40	Summary of New Technology Development Consignment Agreement between R-Tech Ueno and the Japan Agency for Medical Research and Development, dated April 1, 2015 Exhibit 10.40 Summary of New Technology Development Consignment Agreement between R-Tech Ueno and the Japan Agency for Medical Research and Development, dated April 1, 2015 Under this Agreement, the Japan Agency for Medical Research and Development (“AMED”) agreed to lend R-Tech Ueno Ltd. (“R-Tech”) costs for the development of unoprostone 0.15% eye drops (“unoprostone”) for the treatment of retin
March 11, 2016	EX-10.38	CREDIT AGREEMENT Exhibit 10.38 CREDIT AGREEMENT This Credit Agreement (as may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”) is entered into as of October 16, 2015, among Sucampo Pharmaceuticals, Inc., a Delaware corporation, each financial institution from time to time party hereto (collectively, the “Lenders” and individually, a “Lender”), and
March 11, 2016	EX-21	SUBSIDIARIES OF COMPANY EXHIBIT 21 SUBSIDIARIES OF COMPANY Subsidiary State or other jurisdiction of incorporation or organization Sucampo Pharma Americas, LLC Delaware Sucampo LLC Delaware Sucampo AG Switzerland Sucampo Pharma, LLC Japan Sucampo Pharma Europe Ltd. United Kingdom R-Tech Ueno, Ltd. Japan Sucampo Acquisitions GmbH Switzerland
March 11, 2016	EX-10.41	Basic Transaction Agreement Concerning Outsourced Manufacturing R-Tech Ueno, Ltd. Nissan Chemical Industries, Ltd. Confidential and Proprietary Basic Transaction Agreement Concerning Outsourced Manufacturing Exhibit 10.41 Basic Transaction Agreement Concerning Outsourced Manufacturing R-Tech Ueno, Ltd. Nissan Chemical Industries, Ltd. Confidential and Proprietary CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPA
March 8, 2016	EX-99.1	Sucampo Reports Continued Strong Performance for Fourth Quarter and Full Year 2015 Results Driven by Continued AMITIZA Growth and R-TECH UENO Acquisition Company Reiterates 2016 Guidance Company to Host Conference Call Today at 8:30 a.m. EST EdgarFiling EXHIBIT 99.1 Sucampo Reports Continued Strong Performance for Fourth Quarter and Full Year 2015 Results Driven by Continued AMITIZA Growth and R-TECH UENO Acquisition Company Reiterates 2016 Guidance Company to Host Conference Call Today at 8:30 a.m. EST ROCKVILLE, Md., March 08, 2016 (GLOBE NEWSWIRE) - Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical c
March 8, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2016 Sucampo Pharmaceuticals, Inc.
March 8, 2016	EX-99.2	EX-99.2 EX-99.2 3 exh992.htm EXHIBIT 99.2 EXHIBIT 99.2
February 16, 2016	SC 13D	SCMP / Sucampo Pharmaceuticals, Inc. / S&R Foundation - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) David N. Oakey, Esquire McGuireWoods LLP 800 East Canal Street Richmond, VA 23219 (804) 775-1022 (Name, Address and Telephone
February 16, 2016	SC 13G/A	SCMP / Sucampo Pharmaceuticals, Inc. / Kuno Sachiko - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Amendment No. 8 SUCAMPO PHARMACEUTICALS, INC. (Name of Issuer) CLASS A COMMON STOCK (Title of Class of Securities) 864909106 (CUSIP Number) DECEMBER 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
February 16, 2016	SC 13G/A	SCMP / Sucampo Pharmaceuticals, Inc. / S&R Technology Holdings, LLC - SC 13G AMENDMENT NO. 7 Passive Investment SC 13G/A 1 d142107dsc13ga.htm SC 13G AMENDMENT NO. 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Amendment No. 7 SUCAMPO PHARMACEUTICALS, INC. (Name of Issuer) CLASS A COMMON STOCK (Title of Class of Securities) 864909106 (CUSIP Number) DECEMBER 31, 2015 (Date of Event Which Requires Filing of this Statement) Chec
February 11, 2016	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2016 Sucampo Pharmaceuticals, Inc.
February 11, 2016	EX-99.1	EX-99.1 Exhibit 99.1
January 28, 2016	SC 13G	SCMP / Sucampo Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) SUCAMPO PHARMACEUTICALS INC - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 864909106 - (CUSIP Number) December 31, 2015 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 14, 2016	EX-99.1	Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis Addresses Significant Patient Need Aligned With GI Ex EdgarFiling EXHIBIT 99.1 Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis Addresses Significant Patient Need Aligned With GI Expertise, Strategic Focus Phase 3 Study Expected to be Complete in 2018 ROCKVILLE, Md., Jan. 11, 2016 (GLOBE NEWSWIRE) - Sucam
January 14, 2016	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2016 Sucampo Pharmaceuticals, Inc.
January 11, 2016	EX-99.1	EX-99.1 Exhibit 99.1
January 11, 2016	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2016 Sucampo Pharmaceuticals, Inc.
January 7, 2016	EX-99.1	Sucampo Provides Update to 2015 and Confirms 2016 Financial Guidance Post Closing of R-Tech Ueno Acquisition EX-99.1 2 exh991.htm EXHIBIT 99.1 EXHIBIT 99.1 Sucampo Provides Update to 2015 and Confirms 2016 Financial Guidance Post Closing of R-Tech Ueno Acquisition ROCKVILLE, Md., Jan. 07, 2016 (GLOBE NEWSWIRE) - Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today provided additional detail regarding its previously announced guidance for 2015 and 2016, to inclu
January 7, 2016	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 7, 2016 Sucampo Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33609 30-0520478 (State or Other Jurisdiction of Incorporation) (Commissi
January 5, 2016	CT ORDER	Sucampo Pharmaceuticals RDER UNITED STATES SECURITIES AND EXCHANGE COMMISSION January 5, 2016 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Sucampo Pharmaceuticals, Inc.
December 15, 2015	EX-99.1	Sucampo CEO Peter Greenleaf Appointed Chairman of the Board of Directors EXHIBIT 99.1 Sucampo CEO Peter Greenleaf Appointed Chairman of the Board of Directors ROCKVILLE, Md., Dec. 15, 2015 (GLOBE NEWSWIRE) - Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Peter Greenleaf, Chief Executive Officer, has been appointed Chairman of the Board of Directors, effective January 1, 2016. Mr. Greenleaf was appointed C
December 15, 2015	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2015 Sucampo Pharmaceuticals, Inc.
December 2, 2015	EX-99.1	EX-99.1 EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1
December 2, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2015 Sucampo Pharmaceuticals, Inc.
November 20, 2015	EX-24	POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Exhibit 24 POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents that the undersigned hereby constitutes and appoints Charles McFalls, Financial Reporting Manager, or delegate, signing individually, the undersigned?s true and lawful attorneys-in fact and agents to: (1) Prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the
November 4, 2015	EX-10.1	FIRST AMENDMENT TO OFFICE LEASE AGREEMENT Exhibit 10.1 FIRST AMENDMENT TO OFFICE LEASE AGREEMENT THIS FIRST AMENDMENT TO OFFICE LEASE AGREEMENT (this ?First Amendment?) is made this 14 day of September 2015 (the ?Effective Date?), by and between FOUR IRVINGTON CENTRE ASSOCIATES, LLC, a Maryland limited liability company (?Landlord?), and SUCAMPO PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). W I T N E S S E T H: WHEREAS, pursua
November 4, 2015	8-K	Sucampo Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2015 Sucampo Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33609 30-0520478 (State or Other Juris- diction of Incorporation) (Commi
November 4, 2015	EX-10.2	STRATEGIC ALLIANCE AGREEMENT dated as of August 26, 2015 Sucampo Pharmaceuticals, Inc., Sucampo Pharma, LLC. R-Tech Ueno, Ltd. TABLE OF CONTENTS Exhibit 10.2 STRATEGIC ALLIANCE AGREEMENT dated as of August 26, 2015 among Sucampo Pharmaceuticals, Inc., Sucampo Pharma, LLC. and R-Tech Ueno, Ltd. TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INTERPRETATION Section 1.01 Definitions 2 Section 1.02 Interpretation 8 ARTICLE II TRANSACTION Section 2.01 Strategic Alliance 8 Section 2.02 Obligations of Acquiror 9 Section 2.03 Obligations of the Compan
November 4, 2015	EX-99.1	Sucampo Reports Third Quarter 2015 Financial Results and Provides Corporate Update EX-99.1 2 exh991.htm EXHIBIT 99.1 EXHIBIT 99.1 Sucampo Reports Third Quarter 2015 Financial Results and Provides Corporate Update AMITIZA Revenue Performance Drives Income Growth R-Tech Ueno Tender Offer Achieved Threshold; Sucampo Closed on Debt Financing Company Reiterates 2015 Earnings Guidance Company to Host Conference Call Today at 8:30 a.m. EST ROCKVILLE, Md., Nov. 4, 2015 (GLOBE NEWSWIRE)
November 4, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33609 SUCAM
November 4, 2015	EX-10.3	SHARE PURCHASE AGREEMENT Exhibit 10.3 SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT is made and entered into as of August 26, 2015 (this ?Agreement?), by and among Dr. Ryuji Ueno, an individual (?Seller 1?), Dr. Sachiko Kuno, an individual (?Seller 2?), S&R Technology Holdings, LLC, a Delaware limited liability company (?Seller 3?, and together with Seller 1 and Seller 2, collectively, the ?Sellers?, and each of
November 4, 2015	EX-99.2	EX-99.2 EXHIBIT 99.2
November 4, 2015	EX-10.1	FIRST AMENDMENT TO OFFICE LEASE AGREEMENT Exhibit 10.1 FIRST AMENDMENT TO OFFICE LEASE AGREEMENT THIS FIRST AMENDMENT TO OFFICE LEASE AGREEMENT (this ?First Amendment?) is made this 14 day of September 2015 (the ?Effective Date?), by and between FOUR IRVINGTON CENTRE ASSOCIATES, LLC, a Maryland limited liability company (?Landlord?), and SUCAMPO PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). W I T N E S S E T H: WHEREAS, pursua
October 22, 2015	EX-99.2	Sucampo Closes $250 Million Credit Facility EXHIBIT 99.2 Sucampo Closes $250 Million Credit Facility ROCKVILLE, MD, Oct. 22, 2015 (GLOBE NEWSWIRE) - Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ: SCMP), a global biopharmaceutical company, today announced the closing of a $250.0 million credit facility in connection with the financing of its acquisition of R-Tech Ueno (TSE:4573:JP). The loans under the credit facility were fully allocated

SCMP / Sucampo Pharmaceuticals, Inc. - SEC 보고서, 연례 보고, 기업 사업 설명서

기본 통계

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?